SEARCH

SEARCH BY CITATION

References

  • Adamsky, K., Weizer, O., Amariglio, N., Breda, L., Harmelin, A., Rivella, S., Rachmilewitz, E. & Rechavi, G. (2004) Decreased hepcidin mRNA expression in thalassemic mice. British Journal of Haematology, 124, 123124.
  • Andrews, F.J., Morris, C.J., Lewis, E.J. & Blake, D.R. (1987) Effect of nutritional iron deficiency on acute and chronic inflammation. Annals of the rheumatic diseases, 46, 859865.
  • Ashur-Fabian, O., Adamsky, K., Trakhtenbrot, L., Cohen, Y., Raanani, P., Hardan, I., Nagler, A., Rechavi, G. & Amariglio, N. (2007) Apaf1 in chronic myelogenous leukemia (CML) progression: reduced Apaf1 expression is correlated with a H179R p53 mutation during clinical blast crisis. Cell Cycle, 6, 589594.
  • Atkins, M.B., Kappler, K., Mier, J.W., Isaacs, R.E. & Berkman, E.M. (1995) Interleukin-6-associated anemia: determination of the underlying mechanism. Blood, 86, 12881291.
  • Barak, Y., Juven, T., Haffner, R. & Oren, M. (1993) mdm2 expression is induced by wild type p53 activity. The EMBO journal, 12, 461468.
  • Barollo, M., D'Inca, R., Scarpa, M., Medici, V., Cardin, R., Fries, W., Angriman, I. & Sturniolo, G.C. (2004) Effects of iron deprivation or chelation on DNA damage in experimental colitis. International Journal of Colorectal Disease, 19, 461466.
  • Borsellino, N., Belldegrun, A. & Bonavida, B. (1995) Endogenous interleukin 6 is a resistance factor for cis-diamminedichloroplatinum and etoposide-mediated cytotoxicity of human prostate carcinoma cell lines. Cancer Research, 55, 46334639.
  • Bosari, S., Viale, G., Roncalli, M., Graziani, D., Borsani, G., Lee, A.K. & Coggi, G. (1995) p53 gene mutations, p53 protein accumulation and compartmentalization in colorectal adenocarcinoma. The American Journal of Pathology, 147, 790798.
  • Brummelkamp, T.R., Bernards, R. & Agami, R. (2002) A system for stable expression of short interfering RNAs in mammalian cells. Science, 296, 550553.
  • Chandler, D.B., Barton, J.C., Briggs, III, D.D., Butler, T.W., Kennedy, J.I., Grizzle, W.E. & Fulmer, J.D. (1988) Effect of iron deficiency on bleomycin-induced lung fibrosis in the hamster. The American Review of Respiratory Disease, 137, 8589.
  • Chaston, T.B. & Richardson, D.R. (2003) Iron chelators for the treatment of iron overload disease: relationship between structure, redox activity, and toxicity. American Journal of Hematology, 73, 200210.
  • Chen, H.L. & Carbone, D.P. (1997) p53 as a target for anti-cancer immunotherapy. Molecular Medicine Today, 3, 160167.
  • Chen, L., Mory, Y., Zilberstein, A. & Revel, M. (1988) Growth inhibition of human breast carcinoma and leukemia/lymphoma cell lines by recombinant interferon-beta 2. Proceedings of the National Academy of Sciences of the United States of America, 85, 80378041.
  • Choi, S., Cho, Y., Kim, H. & Park, J. (2007) ROS mediate the hypoxic repression of the hepcidin gene by inhibiting C/EBPalpha and STAT-3. Biochemical and Biophysical Research Communications, 356, 312317.
  • Corradini, P., Inghirami, G., Astolfi, M., Ladetto, M., Voena, C., Ballerini, P., Gu, W., Nilsson, K., Knowles, D.M., Boccadoro, M., Pileri, A. & Dalla-Favera, R. (1994) Inactivation of tumor suppressor genes, p53 and Rb1, in plasma cell dyscrasias. Leukemia, 8, 758767.
  • Courselaud, B., Pigeon, C., Inoue, Y., Inoue, J., Gonzalez, F.J., Leroyer, P., Gilot, D., Boudjema, K., Guguen-Guillouzo, C., Brissot, P., Loreal, O. & Ilyin, G. (2002) C/EBPalpha Regulates Hepatic Transcription of Hepcidin, an Antimicrobial Peptide and Regulator of Iron Metabolism. Cross-talk between C/EBP pathway and iron metabolism. The Journal of Biological Chemistry, 277, 4116341170.
  • Cummings, M.C. (1996) Increased p53 mRNA expression in liver and kidney apoptosis. Biochimica et biophysica acta, 1315, 100104.
  • Deicher, R. & Horl, W.H. (2004) Hepcidin: a molecular link between inflammation and anaemia. Nephrology, Dialysis, Transplantation: Official Publication of the European Dialysis and Transplant Association - European Renal Association, 19, 521524.
  • El-Deiry, W.S., Kern, S.E., Pietenpol, J.A., Kinzler, K.W. & Vogelstein, B. (1992) Definition of a consensus binding site for p53. Nature Genetics, 1, 4549.
  • Gao, J. & Richardson, D.R. (2001) The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents, IV: the mechanisms involved in inhibiting cell-cycle progression. Blood, 98, 842850.
  • Gehrke, S.G., Kulaksiz, H., Herrmann, T., Riedel, H.-D., Bents, K., Veltkamp, C. & Stremmel, W. (2003) Expression of hepcidin in hereditary hemochromatosis: evidence for a regulation in response to the serum transferrin saturation and to non-transferrin-bound iron. Blood, 102, 371376.
  • Gerardi, G., Biasiotto, G., Santambrogio, P., Zanella, I., Ingrassia, R., Corrado, M., Cavadini, P., Derosas, M., Levi, S. & Arosio, P. (2005) Recombinant human hepcidin expressed in Escherichia coli isolates as an iron containing protein. Blood Cells, Molecules & Diseases, 35, 177181.
  • Givon, T., Slavin, S., Haran-Ghera, N., Michalevicz, R. & Revel, M. (1992) Antitumor effects of human recombinant interleukin-6 on acute myeloid leukemia in mice and in cell cultures. Blood, 79, 23922398.
  • Goss, J.A., Seu, P., Gao, F.Q. & Wyllie, S. (2005) Ischemia-reperfusion of rat liver modulates hepcidin in vivo expression. Liver Transplantation: Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 11, 800806.
  • Gudas, J.M., Nguyen, H., Li, T., Sadzewicz, L., Robey, R., Wosikowski, K. & Cowan, K.H. (1996) Drug-resistant breast cancer cells frequently retain expression of a functional wild-type p53 protein. Carcinogenesis, 17, 14171427.
  • Hangaishi, A., Ogawa, S., Imamura, N., Miyawaki, S., Miura, Y., Uike, N., Shimazaki, C., Emi, N., Takeyama, K., Hirosawa, S., Kamada, N., Kobayashi, Y., Takemoto, Y., Kitani, T., Toyama, K., Ohtake, S., Yazaki, Y., Ueda, R. & Hirai, H. (1996) Inactivation of multiple tumor-suppressor genes involved in negative regulation of the cell cycle, MTS1/p16INK4A/CDKN2, MTS2/p15INK4B, p53, and Rb genes in primary lymphoid malignancies. Blood, 87, 49494958.
  • Hatoko, M., Tanaka, A., Kuwahara, M. & Yurugi, S. (2001) Molecular response to ischemia-reperfusion of rat skin: study of expression of p53, p21WAF-1, and Bax proteins, and apoptosis. Annals of Plastic Surgery, 47, 425430.
  • Hentze, M.W., Muckenthaler, M.U. & Andrews, N.C. (2004) Balancing acts: molecular control of mammalian iron metabolism. Cell, 117, 285297.
  • Hilbert, D.M., Kopf, M., Mock, B.A., Kohler, G. & Rudikoff, S. (1995) Interleukin 6 is essential for in vivo development of B lineage neoplasms. The Journal of Experimental Medicine, 182, 243248.
  • Hofseth, L., Saito, S., Hussain, S., Espey, M., Miranda, K., Araki, Y., Jhappan, C., Higashimoto, Y., He, P., Linke, S., Quezado, M., Zurer, I., Rotter, V., Wink, D., Appella, E. & Harris, C. (2003) Nitric oxide-induced cellular stress and p53 activation in chronic inflammation. Proceedings of the National Academy of Sciences of the United States of America, 100, 143148.
  • Hoh, J., Jin, S., Parrado, T., Edington, J., Levine, A.J. & Ott, J. (2002) The p53MH algorithm and its application in detecting p53-responsive genes. Proceedings of the National Academy of Sciences of the United States of America, 99, 84678472.
  • Kaeser, M.D. & Iggo, R.D. (2002) Chromatin immunoprecipitation analysis fails to support the latency model for regulation of p53 DNA binding activity in vivo. Proceedings of the National Academy of Sciences of the United States of America, 99, 95100.
  • Kemp, J.D., Cardillo, T., Stewart, B.C., Kehrberg, E., Weiner, G., Hedlund, B. & Naumann, P.W. (1995) Inhibition of lymphoma growth in vivo by combined treatment with hydroxyethyl starch deferoxamine conjugate and IgG monoclonal antibodies against the transferrin receptor. Cancer Research, 55, 38173824.
  • Komarova, E.A., Diatchenko, L., Rokhlin, O.W., Hill, J.E., Wang, Z.J., Krivokrysenko, V.I., Feinstein, E. & Gudkov, A.V. (1998) Stress-induced secretion of growth inhibitors: a novel tumor suppressor function of p53. Oncogene, 17, 10891096.
  • Lee, P., Peng, H., Gelbart, T., Wang, L. & Beutler, E. (2005) Regulation of hepcidin transcription by interleukin-1 and interleukin-6. Proceedings of the National Academy of Sciences of the United States of America, 102, 19061910.
  • Levine, A.J. (1997) p53, the cellular gatekeeper for growth and division. Cell, 88, 323331.
  • Levine, A.J., Momand, J. & Finlay, C.A. (1991) The p53 tumour suppressor gene. Nature, 351, 453456.
  • Loots, G.G. & Ovcharenko, I. (2004) rVISTA 2·0: evolutionary analysis of transcription factor binding sites. Nucleic Acids Research, 32, W217221.
  • Margulies, L. & Sehgal, P.B. (1993) Modulation of the human interleukin-6 promoter (IL-6) and transcription factor C/EBP beta (NF-IL6) activity by p53 species. The Journal of biological chemistry, 268, 1509615100.
  • Means, Jr, R.T. (2000) The anaemia of infection. Best Practice & Research Clinical Haematology, 13, 151162.
  • Means, Jr, R.T., (2004) Hepcidin and anaemia. Blood Reviews, 18, 219225.
  • Michalovitz, D., Halevy, O. & Oren, M. (1990) Conditional inhibition of transformation and of cell proliferation by a temperature-sensitive mutant of p53. Cell, 62, 671680.
  • Milward, E., Johnstone, D., Trinder, D., Ramm, G. & Olynyk, J. (2007) The nexus of iron and inflammation in hepcidin regulation: SMADs, STATs, and ECSIT. Hepatology, 45, 253256.
  • Moll, U.M., LaQuaglia, M., Benard, J. & Riou, G. (1995) Wild-type p53 protein undergoes cytoplasmic sequestration in undifferentiated neuroblastomas but not differentiated tumors. Proceedings of the National Academy of Sciences of the United States of America, 92, 44074411.
  • Moretta, A. (1997) Molecular mechanisms in cell-mediated cytotoxicity. Cell, 90, 1318.
  • Morris, C.J., Earl, J.R., Trenam, C.W. & Blake, D.R. (1995) Reactive oxygen species and iron – a dangerous partnership in inflammation. The International Journal of Biochemistry & Cell Biology, 27, 109122.
  • Mule, J.J., McIntosh, J.K., Jablons, D.M. & Rosenberg, S.A. (1990) Antitumor activity of recombinant interleukin 6 in mice. Journal of Experimental Medicine, 171, 629636.
  • Nakao, S., Kuwano, T., Ishibashi, T., Kuwano, M. & Ono, M. (2003) Synergistic effect of TNF-alpha in soluble VCAM-1-induced angiogenesis through alpha 4 integrins. Journal of Immunology, 170, 57045711.
  • Nemeth, E., Valore, E.V., Territo, M., Schiller, G., Lichtenstein, A. & Ganz, T. (2003) Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood, 101, 24612463.
  • Nemeth, E., Tuttle, M.S., Powelson, J., Vaughn, M.B., Donovan, A., Ward, D.M., Ganz, T. & Kaplan, J. (2004a) Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science, 306, 20902093.
  • Nemeth, E., Rivera, S., Gabayan, V., Keller, C., Taudorf, S., Pedersen, B.K. & Ganz, T. (2004b) IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. Journal of Clinical Investigation, 113, 12711276.
  • Neri, A., Baldini, L., Trecca, D., Cro, L., Polli, E. & Maiolo, A.T. (1993) p53 gene mutations in multiple myeloma are associated with advanced forms of malignancy. Blood, 81, 128135.
  • Nicolas, G., Chauvet, C., Viatte, L., Danan, J.L., Bigard, X., Devaux, I., Beaumont, C., Kahn, A. & Vaulont, S. (2002) The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. Journal of clinical investigation, 110, 10371044.
  • Niedobitek, G., Agathanggelou, A., Barber, P., Smallman, L.A., Jones, E.L. & Young, L.S. (1993) P53 overexpression and Epstein-Barr virus infection in undifferentiated and squamous cell nasopharyngeal carcinomas. The Journal of Pathology, 170, 457461.
  • Nishizaki, M., Fujiwara, T., Tanida, T., Hizuta, A., Nishimori, H., Tokino, T., Nakamura, Y., Bouvet, M., Roth, J.A. & Tanaka, N. (1999) Recombinant adenovirus expressing wild-type p53 is antiangiogenic: a proposed mechanism for Bystander effect. Clinical Cancer Research, 5, 10151023.
  • Ostermeyer, Anne, G., Runko, E., Winkfield, B., Ahn, B. & Moll Ute, M. (1996) Cytoplasmically sequestered wild-type p53 protein in neuroblastoma is relocated to the nucleus by a C-terminal peptide. Proceedings of the National Academy of Sciences of the United States of America, 93, 1519015194.
  • Pietrangelo, A., Dierssen, U., Valli, L., Garuti, C., Rump, A., Corradini, E., Ernst, M., Klein, C. & Trautwein, C. (2007) STAT3 is required for IL-6-gp130-dependent activation of Hepcidin in vivo. Gastroenterology, 132, 294300.
  • Preudhomme, C., Facon, T., Zandecki, M., Vanrumbeke, M., Lai, J., Nataf, E., Loucheux-Lefebvre, M.H., Kerckaert, J.P. & Fenaux, P. (1992) Rare occurrence of P53 gene mutations in multiple myeloma. British journal of haematology, 81, 440443.
  • Rayanade, R.J., Ndubuisi, M.I., Etlinger, J.D. & Sehgal, P.B. (1998) Regulation of IL-6 signaling by p53: STAT3- and STAT5-masking in p53-Val135-containing human hepatoma Hep3B cell lines. Journal of Immunology, 161, 325334.
  • Richardson, D.R. (2002) Iron chelators as therapeutic agents for the treatment of cancer. Critical Reviews in Oncology/Hematology, 42, 267281.
  • Ropke, M., Hald, J., Guldberg, P., Zeuthen, J., Norgaard, L., Fugger, L., Svejgaard, A., Burg, Sjoerd Van, D., Nijman Hans, W., Melief Cornelis, J.M. & Claesson Mogens, H. (1996) Spontaneous human squamous cell carcinomas are killed by a human cytotoxic T lymphocyte clone recognizing a wild-type p53-derived peptide. Proceedings of the National Academy of Sciences of the United States of America, 93, 1470414707.
  • Santhanam, U., Ray, A. & Sehgal, P.B. (1991) Repression of the interleukin 6 gene promoter by p53 and the retinoblastoma susceptibility gene product. Proceedings of the National Academy of Sciences of the United States of America, 88, 76057609.
  • Shaulsky, G., Goldfinger, N., Peled, A. & Rotter, V. (1991a) Involvement of wild-type p53 protein in the cell cycle requires nuclear localization. Cell Growth & Differentiation: The Molecular Biology Journal of the American Association for Cancer Research, 2, 661667.
  • Shaulsky, G., Goldfinger, N., Tosky, M., Levine, A.J. & Rotter, V. (1991b) Nuclear localization is essential for the activity of p53 protein. Oncogene, 6, 20552065.
  • Siemann, D.W., Chaplin, D.J. & Horsman, M.R. (2004) Vascular-targeting therapies for treatment of malignant disease. Cancer, 100, 24912499.
  • Simonart, T., Degraef, C., Andrei, G., Mosselmans, R., Hermans, P., Van Vooren, J.P., Noel, J.C., Boelaert, J.R., Snoeck, R. & Heenen, M. (2000) Iron chelators inhibit the growth and induce the apoptosis of Kaposi's sarcoma cells and of their putative endothelial precursors. The Journal of Investigative Dermatology, 115, 893900.
  • Srisuma, S., Biswal, S.S., Mitzner, W.A., Gallagher, S.J., Mai, K.H. & Wagner, E.M. (2003) Identification of genes promoting angiogenesis in mouse lung by transcriptional profiling. American Journal of Respiratory Cell and Molecular Biology, 29, 172179.
  • Tak, P.P., Zvaifler, N.J., Green, D.R. & Firestein, G.S. (2000) Rheumatoid arthritis and p53: how oxidative stress might alter the course of inflammatory diseases. Immunology Today, 21, 7882.
  • Theobald, M., Biggs, J., Dittmer, D., Levine, A.J. & Sherman, L.A. (1995) Targeting p53 as a General Tumor Antigen. Proceedings of the National Academy of Sciences of the United States of America, 92, 1199311997.
  • Verga Falzacappa, M.V., Vujic Spasic, M., Kessler, R., Stolte, J., Hentze, M.W. & Muckenthaler, M.U. (2007) STAT3 mediates hepatic hepcidin expression and its inflammatory stimulation. Blood, 109, 353358.
  • Vidal-Vanaclocha, F., Fantuzzi, G., Mendoza, L., Fuentes, A.M., Anasagasti, M.J., Martin, J., Carrascal, T., Walsh, P., Reznikov, L.L., Kim, S.H., Novick, D., Rubinstein, M. & Dinarello, C.A. (2000) IL-18 regulates IL-1beta-dependent hepatic melanoma metastasis via vascular cell adhesion molecule-1. Proceedings of the National Academy of Sciences of the United States of America, 97, 734739.
  • Vousden, K.H. & Lu, X. (2002) Live or let die: the cell's response to p53. Nature Reviews Cancer, 2, 594604.
  • Weinberg, E.D. (1999a) Iron loading and disease surveillance. Emerging Infectious Diseases, 5, 346352.
  • Weinberg, E.D. (1999b) Development of clinical methods of iron deprivation for suppression of neoplastic and infectious diseases. Cancer Investigation, 17, 507513.
  • Wrighting, D.M. & Andrews, N.C. (2006) Interleukin-6 induces hepcidin expression through STAT3. Blood, 108, 32043209.
  • Yang, D.C., Jiang, X.P., Elliott, R.L. & Head, J.F. (2001) Inhibition of growth of human breast carcinoma cells by an antisense oligonucleotide targeted to the transferrin receptor gene. Anticancer Research, 21, 17771787.
  • Yasuga, Y., Hirosawa, S., Yamamoto, K., Tomiyama, J., Nagata, J. & Aokia, N. (1995) N-ras and p53 gene mutations are very rare events in multiple myeloma. International Journal of Hematology, 62, 9197.
  • Zhou, X., Wang, X.W., Xu, L., Hagiwara, K., Nagashima, M., Wolkowicz, R., Zurer, I., Rotter, V. & Harris, C.C. (1999) COOH-terminal domain of p53 modulates p53-mediated transcriptional transactivation, cell growth, and apoptosis. Cancer Research, 59, 843848.